aTyr Pharma, Inc. (ATYR) Stock Forecast & Price Target
aTyr Pharma, Inc. · NASDAQ
$0.50+0.01 (+2.02%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering aTyr Pharma, Inc, 2 rate it Buy or better, 7 sit at Hold, and 0 rate it Sell or worse, a hold consensus. The target range is very wide, $1.00 to $17.00 (about 17.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $5.63 sits 1025% above the current $0.50. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Hold
Strong Buy00%
Buy222%
Hold778%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to aTyr Pharma, Inc.
As of Jul, 2 of 9 firms rate ATYR a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ATYR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.18 – $-0.10 · 8 analysts · -46% YoY
Next period, 8 analysts expect aTyr Pharma, Inc. to earn $-0.14 a share (range $-0.18 – $-0.10), versus $-0.26 a year earlier. Full-year consensus is $-0.56, growing to $-0.61 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering aTyr Pharma, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ATYR.
#1
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$20.00+3900.8% to target
Overall win rate
34%
+ Follow
#2
Gregory Renza
RBC Capital · Rank #179
Buy
$16.00+3100.6% to target
Overall win rate
34%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Hold
No targeton ATYR
Overall win rate
32%
+ Follow
#4
Brian Abrahams
RBC Capital · Rank #311
Hold
$1.00+100.0% to target
Overall win rate
25%
+ Follow
#5
Derek Archila
Wells Fargo · Rank #350
Hold
$1.00+100.0% to target
Overall win rate
32%
+ Follow
ATYR stock forecast FAQ
What is ATYR's average 12-month price target?+
The 4 analysts with a live target average $5.63 for aTyr Pharma, Inc. over the next 12 months, ranging from a $17.00 high to a $1.00 low.
Is ATYR stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 9 analyst ratings, 2 are Buy or Strong Buy, 7 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ATYR?+
The Street-high target is $17.00 (Jefferies), and the Street-low is $1.00 (RBC Capital). The average of all 4 active targets is $5.63.
How many Wall Street analysts cover ATYR?+
9 analysts have an active rating on aTyr Pharma, Inc., and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ATYR?+
Among analysts who currently cover ATYR, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #152). Their current call is Buy with a $20.00 target.
What is aTyr Pharma, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.18 – $-0.10) across 8 analysts. Full-year EPS is projected at $-0.56, rising to $-0.61 the following year.
How much revenue is aTyr Pharma, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ATYR lately?+
As of Jul, 2 of 9 firms rate ATYR a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ATYR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
